We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
-5.72%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$7.95B
AUM Growth
+$407M
Cap. Flow
+$737M
Cap. Flow %
9.28%
Top 10 Hldgs %
63.45%
Holding
409
New
72
Increased
88
Reduced
65
Closed
155

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$49.7M
2
SUPN icon
Supernus Pharmaceuticals
SUPN
+$49.3M
3
IMCR icon
Immunocore
IMCR
+$41.4M
4
EXAS
Exact Sciences
EXAS
+$36.8M
5
IMVT icon
Immunovant
IMVT
+$35.1M

Top Sells

Rank Stock Value
1
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$92.8M
2
KO icon
Coca-Cola
KO
+$36M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$31.9M
4
POST icon
Post Holdings
POST
+$26.8M
5
NOMD icon
Nomad Foods
NOMD
+$26.4M

Sector Composition

Rank Sector Weight
1 Healthcare 33.06%
2 Consumer Staples 5.21%
3 Consumer Discretionary 4.94%
4 Technology 3.72%
5 Materials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GNLX icon
151
Genelux
GNLX
$132M
$1.75M 0.02%
+900,000
New +$3.06M
WKSP icon
152
Worksport
WKSP
$9.71M
$1.72M 0.02%
220,676
+26,865
+14% +$164K
VINC
153
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
$1.61M 0.02%
+99,400
New +$2.49M
AIM
154
AIM ImmunoTech
AIM
$7.03M
$1.52M 0.02%
+40,821
New +$1.73M
DPRO
155
Draganfly
DPRO
$153M
$1.51M 0.02%
+258,920
New +$1.61M
CANF
156
Can-Fite BioPharma American Depositary Shares
CANF
$6.75M
$1.34M 0.02%
25,943
+6,803
+36% +$322K
APTO
157
DELISTED
Aptose Biosciences, Inc.
APTO
$1.3M 0.02%
+57,100
New +$1.94M
BNGO icon
158
Bionano Genomics
BNGO
$12.3M
$1.14M 0.01%
+27,967
New +$1.54M
EVAX
159
Evaxion A/S
EVAX
$23.5M
$1.14M 0.01%
78,400
+5,000
+7% +$91.4K
TARA icon
160
Protara Therapeutics
TARA
$220M
$1.08M 0.01%
+520,000
New +$1.52M
VTGN icon
161
VistaGen Therapeutics
VTGN
$9.89M
$1.04M 0.01%
300,000
-64,000
-18% -$277K
NKTR icon
162
Nektar Therapeutics
NKTR
$2.39B
$1.04M 0.01%
+55,733
New +$1.17M
DXCM icon
163
DexCom
DXCM
$31.5B
$944K 0.01%
+8,328
New +$1.05M
NEUP
164
Neuphoria Therapeutics
NEUP
$21M
$941K 0.01%
+102,230
New +$1.11M
ARAY icon
165
Accuray
ARAY
$32M
$910K 0.01%
+500,000
New +$953K
KYNB
166
CALL
Kyntra Bio
KYNB
$27.2M
$892K 0.01%
40,000
– –
AYTU icon
167
AYTU BioPharma
AYTU
$23.9M
$736K 0.01%
+252,000
New +$761K
IKT icon
168
Inhibikase Therapeutics
IKT
$342M
$713K 0.01%
+589,575
New +$1.02M
VIVS
169
VivoSim Labs
VIVS
$1.2M
$708K 0.01%
+77,417
New +$914K
AWH
170
DELISTED
Aspira Women's Health Inc. Common Stock
AWH
$697K 0.01%
468,000
-689,000
-60% -$1.81M
CTM icon
171
Castellum
CTM
$68M
$660K 0.01%
3,547,987
-1,108,000
-24% -$256K
XRT icon
172
State Street SPDR S&P Retail ETF
XRT
$449M
$658K 0.01%
+8,782
New +$656K
CLX icon
173
Clorox
CLX
$11.6B
$619K 0.01%
+4,538
New +$630K
VCNX
174
DELISTED
Vaccinex, Inc. Common Stock
VCNX
$610K 0.01%
94,000
-51,000
-35% -$308K
PPBT
175
Purple Biotech
PPBT
$1.31M
$553K 0.01%
6,790
-3,785
-36% -$439K
5 6
7
8 9

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return

Armistice Capital's Q2 2024 Portfolio in Review

As of Q2 2024, Armistice Capital held 409 positions worth $7.95B, up 5.4% from $7.54B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Armistice Capital deployed $737M of net new capital in Q2 2024, opening 72 new positions and adding to 88 existing holdings. Its largest new stake was Simply Good Foods: 957,163 shares worth $34.6M.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, down from 34% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Coca-Cola, an estimated $36M trimmed.

  • Armistice Capital's largest Q2 2024 buy was Simply Good Foods: 957,163 shares worth $34.6M.
  • Armistice Capital added most to Alkermes in Q2 2024, an estimated $49.7M increase.
  • Armistice Capital's biggest Q2 2024 reduction was Coca-Cola, cutting an estimated $36M.
  • Armistice Capital fully exited Deciphera Pharmaceuticals, Inc. Common Stock in Q2 2024, selling an estimated $92.8M.
  • Armistice Capital's ten largest holdings make up 63% of its $7.95B portfolio in Q2 2024.
  • Armistice Capital opened 72 new positions and closed 155 in Q2 2024.
  • Armistice Capital's portfolio value rose 5.4% quarter-over-quarter to $7.95B.

Based on Armistice Capital's 13F filing for Q2 2024, filed 14 Aug 2024.